In 2022, we used NCI-H1650 cells, the primary human NSCLC, and HUVECs to construct a lung-on-a-chip platform for evaluating the response of lung cancer cells to epidermal growth factor receptor (EGFR)-targeted drugs (Tan et al., 2022). Here, EGFR is linked to lung cancer.